Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ViaCyte gets $10.6mm via Series C-1 financing; adds $5.4mm

Executive Summary

Regenerative medicine company ViaCyte Inc. has raised $10.6mm by selling Series C-1 preferred shares to returning investors Johnson & Johnson Development Corp., Sanderling Ventures, and Asset Management Co. The company also issued warrants. ViaCyte will use the proceeds from the financing to initiate clinical trials--anticipated for the first half of 2014--of its VC01 encapsulated cell therapy candidate for Type I diabetes. ViaCyte was already awarded $10.1mm from CIRM to study VC01.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies